Background
Extensive literature review revealed that no RP–LC method has been developed for simultaneous estimation of EMPA, LINA and MET in combined dosage form. This is a newer combination approved by USFDA on 4th June 2019 and it is launch in the United State Market on 27th January 2020.
Result
A simple, sensitive, specific, precise and accurate reverse phase—high performance liquid chromatography (RP- HPLC) method has been developed for simultaneous estimation of Empagliflozin, Linagliptin and Metformin HCl in bulk and synthetic mixture. Phenomenex C18 column (250 mm × 4.6 mm, 5 µm) was used as stationary phase for chromatographic separation through isocratic elution using Acetonitrile: Methanol: Water in a ratio (27: 20: 53, v/v/v) pH 4 adjusted with 1% Ortho-phosphoric acid as mobile phase at flow rate 1 ml/min. PDA detector was used for simultaneous analysis of all three drugs at common wavelength 223 nm and the each injection volume was 20 µl. The linearity range for Empagliflozin, Linagliptin and Metformin HCl was found to be 0.5–5 µg/ml, 0.25–2.5 µg/ml, and 50–500 µg/ml, respectively. The retention time for Empagliflozin, Linagliptin and Metformin HCl was found to be 14.5 min, 3.4 min and 2.01 min, respectively. The percentage (%) recovery was found to be 99.98–100.81% for Empagliflozin, 99.33–100.57% for Linagliptin and 100.65–101.35% for Metformin HCl respectively.
Conclusion
As per the international Conference on Harmonisation (ICH) Q2 (R1) guideline, proposed RP–LC method validation has been carried out. The proposed RP–LC method was repeatable and selective as per statistical analysis and it can be use for simultaneous estimation of Empagliflozin, Linagliptin and Metformin HCl in bulk and synthetic mixture. The proposed method might be applied for simultaneous estimation of all three drugs in pharmaceutical formulation.
An accurate, sensitive, robust and precise high performance thin layer liquid chromatography method was developed based on ICH Q2 (R1) guidelines for estimation of novel combination of Amlodipine besylate, Rosuvastatin calcium and Fimasartan potassium in bulk and its synthetic mixture. Pre-coated silica gel aluminum plate 60 F254 was selected as the stationary phase and n-hexane, n-butanol, methanol, and Glacial Acetic Acid (5.7:2:2.3:0.1, v/v/v/v) was selected as mobile phase. All three drugs showing appreciable absorbance at the common wavelength of 242 nm were selected for quantification of Amlodipine besylate, Rosuvastatin calcium, and Fimasartan potassium, respectively. The method was validated for linearity, precision, accuracy, and robustness, limit of detection and limit of quantitation as per ICH parameters. The regression coefficients (r2) were found to be 0.9986, 0.9975 and 0.9988 for Amlodipine besylate, Rosuvastatin calcium, and Fimasartan potassium, respectively. The average percentage recovery of Amlodipine besylate, Rosuvastatin calcium and Fimasartan potassium were found to be 99.38-100-60%, 99.75-100.63%, 99.39-100%, respectively. Thin Layer Chromatographic method has prospective qualitative as well as quantitative applications for concurrent estimation of Amlodipine besylate, Rosuvastatin calcium and Fimasartan potassium in bulk and pharmaceutical dosage form.
The proposed sensitive, precise, and accurate reverse phase-liquid chromatography (RP-LC) method is used for simultaneous estimation Amlodipine besylate, Rosuvastatin calcium and Fimasartan potassium trihydrate in bulk and synthetic mixture which is under phase 3 trial. An accurate and cost effective isocratic approach is employed by using Phenomenex C-18 column (250 mm × 4.6 mm, 5 μm). A method was developed and validated by focusing on ICH Q2 (R1) guideline parameters, efficient separation of all three drugs were obtained by optimised solvent mixture of acetonitrile and 0.02 M potassium dihydrogen phosphate buffer (49:51, v/v) pH 3.0 adjusted with 1% O-phosphoric acid used as mobile phase, flow rate was maintained 1 ml/min and analysis was carried out by using PDA detector at common wavelength 242 nm. The linearity ranges were found to be 1-7 μg/mL for Amlodipine besylate with correlation coefficient (r 2 ) 0.9966, 2-12 μg/ mL for Rosuvastatin calcium with correlation coefficient (r 2 ) 0.9998 and 6-36 μg/mL for Fimasartan potassium trihydrate with correlation coefficient (r 2 ) 0.9990, respectively. The proposed LC method has potential qualitative as well as quantitative applications for simultaneous estimation of Amlodipine besylate, Rosuvastatin calcium and Fimasartan potassium trihydrate in bulk and synthetic mixture.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.